Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENOVATE: Rivaroxaban vs Warfarin After Mechanical Aortic Valve Replacement
NCT04258488Phase 4Recruiting
- Start
- Feb 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rivaroxaban in thromboembolism (2 arms). Primary endpoint: Event rate of the composite of cardiac death, valve thrombosis, valve-related thromboembolic event, major bleeding, and clinically-relevant non-major bleeding at 1 year. Started Feb 2022; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT04258488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258488.